NCT03522662Unknown2 期
An Experimental Medicine Study to Characterise the Importance of IL-18 Production and to Evaluate the Therapeutic Potential of IL-18 Blockade With GSK1070806 in Subjects With Behcet's Disease
适应症
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- The occurrence of all moderate, severe and life threatening adverse events
研究概览
简要总结
The primary outcome measure of the study is to demonstrate the safety and tolerability of GSK1070806 in the Behcet's disease population at 24 weeks, with biochemical and clinical efficacy and mechanistic studies to further explore the pathogenesis of Behcet's disease important secondary and exploratory outcomes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have given written informed consent to participate
- •Be aged 18 years and over
- •Have a diagnosis of Behcet's disease (according to the International Study Group (ISG) diagnostic guidelines or International Criteria for BD (ICBD)).
- •Have active disease, severe enough to necessitate the use of biological therapy at the time of enrolment (i.e. Subjects have refractory disease as defined by the UK Centres of Excellence criteria as failure to respond to steroid and/or immunosuppressive therapy with significant or major organ-threatening disease.
排除标准
- •Age under 18 years
- •Allergies to humanized monoclonal antibodies
- •Subjects who have received any of the following agents within 364 days of day 0:
- •Alemtuzumab
- •Rituximab or any other B cell depleting or modulating biological agent
- •Subjects who have received any of the following agents within 180 days of day 0:
- •Cyclophosphamide
- •Anti-thymocyte globulin
- •Subjects who have received any of the following agents within 90 days of Day 0:
- •Intravenous immunoglobulin (IVIG)
- •Plasmapheresis
- •Subjects who have received any of the following agents within 30 days of Day 0:
- •Anti-TNF (e.g. adalimumab, etanercept, infliximab)
- •Anti-IL-6 therapy (e.g. tocilizumab)
- •Interleukin-1 receptor antagonist (e.g. anakinra)
- •Alpha interferon
- •Any live vaccine
- •Subjects who have received any other investigational product within 30 days, 5 half lives or twice the duration of the biological effect, whichever is longer.
- •Subjects required more than 15mg prednisolone daily in the 4 week run in phase.
- •Positive human immunodeficiency virus (HIV) antibody test
- •Positive serology for Hepatitis B (HB), defined as: (i) HB surface antigen positive (HBsAg+) OR (ii) HB core antibody positive (HBcAb+)
- •Positive Hepatitis C (HCV) antibody test
- •Evidence of active or latent tuberculosis (TB) as documented by medical history and examination, chest X-rays (posterior anterior and lateral), and a positive (not indeterminate) QuantiFERON®-TB Gold test.
- •Evidence of chronic infection requiring long term antimicrobial therapy
- •Serum IgG level < 3g/l
- •Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, and carcinoma in situ of the uterine cervix.
- •QTc interval (single or average) > 480msec or in subjects with bundle branch block QTc > 500msec (these criteria do not apply to subjects with predominantly paced rhythm).
- •Liver function: ALT > 2xULN and bilirubin > 1.5 ULN (isolated bilirubin > 1.5 ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%)
- •Compliance: is unlikely to comply with scheduled study visits based on investigator judgment or has a history of substance abuse, psychiatric disorder or condition that may compromise communication with the investigator
- •Women who are pregnant or breast feeding
- •Women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for one month before and 12 months after administration of GSK1070806
结局指标
主要结局
The occurrence of all moderate, severe and life threatening adverse events
时间窗: 24 weeks
Events that that are possibly, probably or definitely attributable to a single IV dose of GSK1070806 (10mg/kg)
次要结局
- Measurement of the accumulation of damage(24 weeks)
- All adverse events, including mild events(24 weeks)
- Measurement of disease activity(24 weeks)
研究者
Dr. Rona Smith
Dr Rona Smith
Cambridge University Hospitals NHS Foundation Trust
研究点 (2)
Loading locations...
相似试验
招募中
1 期
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)NeoplasmsNCT06551142GlaxoSmithKline845
招募中
1 期
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)Solid TumorsNeoplasmsNCT06431594GlaxoSmithKline675
Unknown
1 期
A Study to Evaluate the Safety and Tolerability of Multiple Doses of Gerilimzumab in Rheumatoid Arthritis PatientsRheumatoid ArthritisNCT04179513Genor Biopharma Co., Ltd.24
已完成
1 期
A Study of CL-197 Capsules in Healthy ParticipantsHIV-1NCT05944848HeNan Sincere Biotech Co., Ltd44
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic InsufficiencySafety, Tolerability, and PK of NBI-98854 in Hepatically Impaired SubjectsNCT01916993Neurocrine Biosciences24